Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGTX 
MeiraGTx Holdings PLC (MGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: MGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.5
1 Year Target Price $27.5
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.98% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 631.05M USD | Price to earnings Ratio - | 1Y Target Price 27.5 |
Price to earnings Ratio - | 1Y Target Price 27.5 | ||
Volume (30-day avg) 5 | Beta 1.38 | 52 Weeks Range 4.55 - 9.73 | Updated Date 12/1/2025 |
52 Weeks Range 4.55 - 9.73 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.5 | Actual -0.62 |
Profitability
Profit Margin - | Operating Margin (TTM) -11231.95% |
Management Effectiveness
Return on Assets (TTM) -41.91% | Return on Equity (TTM) -611.42% |
Valuation
Trailing PE - | Forward PE 1.61 | Enterprise Value 741294378 | Price to Sales(TTM) 23.02 |
Enterprise Value 741294378 | Price to Sales(TTM) 23.02 | ||
Enterprise Value to Revenue 27.04 | Enterprise Value to EBITDA -3.29 | Shares Outstanding 80490889 | Shares Floating 34163553 |
Shares Outstanding 80490889 | Shares Floating 34163553 | ||
Percent Insiders 19.99 | Percent Institutions 65.19 |
Upturn AI SWOT
MeiraGTx Holdings PLC
Company Overview
History and Background
MeiraGTx Holdings PLC is a clinical-stage gene therapy company founded in 2015. It focuses on developing gene therapies for a range of serious diseases. The company has made significant strides in advancing its pipeline of gene therapy candidates.
Core Business Areas
- Gene Therapy Development: Focuses on developing and commercializing gene therapies for ocular, salivary gland, and neurodegenerative diseases.
Leadership and Structure
The leadership team consists of experienced professionals in gene therapy development and commercialization. The organizational structure is designed to support research, clinical development, and manufacturing.
Top Products and Market Share
Key Offerings
- AAV2-hAQP1 (Xerostomia): Gene therapy for radiation-induced xerostomia (dry mouth) following head and neck cancer treatment. It's in Phase 3. Competitors include artificial saliva products, prescription medications such as pilocarpine, and other companies developing therapies for xerostomia.
- AAV-RPGR (XLRP): Gene therapy for X-linked retinitis pigmentosa (XLRP), a genetic eye disease. It's in Phase 3. Competitors include other gene therapy companies targeting inherited retinal diseases like XLRP, such as those from Adverum Biotechnologies.
- AAV-CNGB3 (Achromatopsia): Gene therapy candidate for achromatopsia, a genetic disorder causing color blindness and visual impairment. Competitors include other gene therapy companies, such as Kodiak Sciences and Vedere Bio.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, with increasing investment and regulatory support for innovative therapies. There's strong demand for treatments for genetic diseases with limited or no existing options.
Positioning
MeiraGTx is positioned as a clinical-stage gene therapy company focusing on addressing unmet needs in ocular, salivary gland, and neurodegenerative diseases. Its competitive advantage lies in its proprietary gene therapy platform and experienced team.
Total Addressable Market (TAM)
The global gene therapy market is projected to reach billions of dollars. MeiraGTx is positioned to capture a significant portion of this market by addressing specific disease areas like XLRP and xerostomia.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platform
- Experienced management team
- Advanced clinical pipeline
- Focus on unmet medical needs
Weaknesses
- High research and development costs
- Regulatory hurdles
- Manufacturing complexities
- Reliance on partnerships
Opportunities
- Expanding clinical pipeline
- Strategic partnerships and collaborations
- Regulatory approvals
- Market expansion into new geographies
Threats
- Competition from other gene therapy companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- ADVM
- VKTX
- RDHL
Competitive Landscape
MeiraGTx faces competition from other gene therapy companies with similar targets. Success depends on clinical trial outcomes and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and partnerships.
Future Projections: Future growth is dependent on clinical trial success and regulatory approvals. Analyst estimates are speculative and subject to change.
Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and expanding manufacturing capabilities.
Summary
MeiraGTx is a clinical-stage gene therapy company with a promising pipeline. While it faces inherent risks in drug development and regulatory hurdles, its focus on unmet medical needs and strategic partnerships provide opportunities for growth. Success hinges on positive clinical trial outcomes and effective market access strategies. The company needs to maintain a healthy cash flow to support its costly R&D activities and navigate the competitive landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (limited access)
- Industry news
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MeiraGTx Holdings PLC
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-06-08 | CEO, President & Director Dr. Alexandria Forbes Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 409 | Website https://meiragtx.com |
Full time employees 409 | Website https://meiragtx.com | ||
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.